23Jun 2023
Safety, tolerability, pharmacokinetics, and immunogenicity of an anti-SARS-CoV-2 monoclonal antibody HFB30132A after single dose intravenous administration in healthy Chinese subjects: a phase 1, randomized, double-blind, placebo-controlled study

Safety, tolerability, pharmacokinetics, and immunogenicity of an anti-SARS-CoV-2 monoclonal antibody HFB30132A after single dose intravenous administration in healthy Chinese subjects: a phase 1, randomized, double-blind, placebo-controlled study

Promising results from a phase 1 clinical trial evaluating HFB30132A, an anti-SARS-CoV-2 monoclonal antibody, have been reported. The study found that HFB30132A was safe and well-tolerated in healthy Chinese subjects, with no immunogenic response detected. The antibody exhibited neutralizing activity against various virus variants and a prolonged half-life. These findings support the potential development of HFB30132A in combating COVID-19

  • #family health

Like

Save

Share